Cargando…

KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8(+) T-cell-dependent antitumor immunity

Background: Immune checkpoint blockers (ICBs) are revolutionized therapeutic strategies for cancer, but most patients with solid neoplasms remain resistant to ICBs, partly because of the difficulty in reversing the highly immunosuppressive tumor microenvironment (TME). Exploring the strategies for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qi, Liu, Zhou, Gao, Zhijie, Luo, Yao, Li, Fubing, Yang, ChuanYu, Wang, Tiantian, Meng, Xiangyu, Chen, Haijun, Li, Juanjuan, Kong, Yanjie, Dong, Chao, Sun, Si, Chen, Ceshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008740/
https://www.ncbi.nlm.nih.gov/pubmed/36923542
http://dx.doi.org/10.7150/thno.82182
_version_ 1784905826164539392
author Wu, Qi
Liu, Zhou
Gao, Zhijie
Luo, Yao
Li, Fubing
Yang, ChuanYu
Wang, Tiantian
Meng, Xiangyu
Chen, Haijun
Li, Juanjuan
Kong, Yanjie
Dong, Chao
Sun, Si
Chen, Ceshi
author_facet Wu, Qi
Liu, Zhou
Gao, Zhijie
Luo, Yao
Li, Fubing
Yang, ChuanYu
Wang, Tiantian
Meng, Xiangyu
Chen, Haijun
Li, Juanjuan
Kong, Yanjie
Dong, Chao
Sun, Si
Chen, Ceshi
author_sort Wu, Qi
collection PubMed
description Background: Immune checkpoint blockers (ICBs) are revolutionized therapeutic strategies for cancer, but most patients with solid neoplasms remain resistant to ICBs, partly because of the difficulty in reversing the highly immunosuppressive tumor microenvironment (TME). Exploring the strategies for tumor immunotherapy is highly dependent on the discovery of molecular mechanisms of tumor immune escape and potential therapeutic target. Krüppel-like Factor 5 (KLF5) is a cell-intrinsic oncogene to promote tumorigenesis. However, the cell-extrinsic effects of KLF5 on suppressing the immune response to cancer remain unclear. Methods: We analyzed the immunosuppressive role of KLF5 in mice models transplanted with KLF5-deleted/overexpressing tumor cells. We performed RNA sequencing, immunohistochemistry, western blotting, real time-PCR, ELISA, luciferase assay, chromatin immunoprecipitation (ChIP), and flow cytometry to demonstrate the effects of KLF5 on CD8(+) T cell infiltration and related molecular mechanism. Single-cell RNA sequencing and spatial transcriptomics analysis were applied to further decipher the association between KLF5 expression and infiltrating immune cells. The efficacy of KLF5/COX2 inhibitors combined with anti-programmed cell death protein 1 (anti-PD1) therapy were explored in pre-clinical models. Finally, a gene-expression signature depending on KLF5/COX2 axis and associated immune markers was created to predict patient survival. Results: KLF5 inactivation decelerated basal-like breast tumor growth in a CD8(+) T-cell-dependent manner. Transcriptomic profiling revealed that KLF5 loss in tumors increases the number and activated function of T lymphocytes. Mechanistically, KLF5 binds to the promoter of the COX2 gene and promotes COX2 transcription; subsequently, KLF5 deficiency decreases prostaglandin E2 (PGE2) release from tumor cells by reducing COX2 expression. Inhibition of the KLF5/COX2 axis increases the number and functionality of intratumoral antitumor T cells to synergize the antitumorigenic effects of anti-PD1 therapy. Analysis of patient datasets at single-cell and spatial resolution shows that low expression of KLF5 is associated with an immune-supportive TME. Finally, we generate a KLF5/COX2-associated immune score (KC-IS) to predict patient survival. Conclusions: Our results identified a novel mechanism responsible for KLF5-mediated immunosuppression in TME, and targeting the KLF5/COX2/PGE2 axis is a critical immunotherapy sensitizer.
format Online
Article
Text
id pubmed-10008740
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-100087402023-03-14 KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8(+) T-cell-dependent antitumor immunity Wu, Qi Liu, Zhou Gao, Zhijie Luo, Yao Li, Fubing Yang, ChuanYu Wang, Tiantian Meng, Xiangyu Chen, Haijun Li, Juanjuan Kong, Yanjie Dong, Chao Sun, Si Chen, Ceshi Theranostics Research Paper Background: Immune checkpoint blockers (ICBs) are revolutionized therapeutic strategies for cancer, but most patients with solid neoplasms remain resistant to ICBs, partly because of the difficulty in reversing the highly immunosuppressive tumor microenvironment (TME). Exploring the strategies for tumor immunotherapy is highly dependent on the discovery of molecular mechanisms of tumor immune escape and potential therapeutic target. Krüppel-like Factor 5 (KLF5) is a cell-intrinsic oncogene to promote tumorigenesis. However, the cell-extrinsic effects of KLF5 on suppressing the immune response to cancer remain unclear. Methods: We analyzed the immunosuppressive role of KLF5 in mice models transplanted with KLF5-deleted/overexpressing tumor cells. We performed RNA sequencing, immunohistochemistry, western blotting, real time-PCR, ELISA, luciferase assay, chromatin immunoprecipitation (ChIP), and flow cytometry to demonstrate the effects of KLF5 on CD8(+) T cell infiltration and related molecular mechanism. Single-cell RNA sequencing and spatial transcriptomics analysis were applied to further decipher the association between KLF5 expression and infiltrating immune cells. The efficacy of KLF5/COX2 inhibitors combined with anti-programmed cell death protein 1 (anti-PD1) therapy were explored in pre-clinical models. Finally, a gene-expression signature depending on KLF5/COX2 axis and associated immune markers was created to predict patient survival. Results: KLF5 inactivation decelerated basal-like breast tumor growth in a CD8(+) T-cell-dependent manner. Transcriptomic profiling revealed that KLF5 loss in tumors increases the number and activated function of T lymphocytes. Mechanistically, KLF5 binds to the promoter of the COX2 gene and promotes COX2 transcription; subsequently, KLF5 deficiency decreases prostaglandin E2 (PGE2) release from tumor cells by reducing COX2 expression. Inhibition of the KLF5/COX2 axis increases the number and functionality of intratumoral antitumor T cells to synergize the antitumorigenic effects of anti-PD1 therapy. Analysis of patient datasets at single-cell and spatial resolution shows that low expression of KLF5 is associated with an immune-supportive TME. Finally, we generate a KLF5/COX2-associated immune score (KC-IS) to predict patient survival. Conclusions: Our results identified a novel mechanism responsible for KLF5-mediated immunosuppression in TME, and targeting the KLF5/COX2/PGE2 axis is a critical immunotherapy sensitizer. Ivyspring International Publisher 2023-02-21 /pmc/articles/PMC10008740/ /pubmed/36923542 http://dx.doi.org/10.7150/thno.82182 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Wu, Qi
Liu, Zhou
Gao, Zhijie
Luo, Yao
Li, Fubing
Yang, ChuanYu
Wang, Tiantian
Meng, Xiangyu
Chen, Haijun
Li, Juanjuan
Kong, Yanjie
Dong, Chao
Sun, Si
Chen, Ceshi
KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8(+) T-cell-dependent antitumor immunity
title KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8(+) T-cell-dependent antitumor immunity
title_full KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8(+) T-cell-dependent antitumor immunity
title_fullStr KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8(+) T-cell-dependent antitumor immunity
title_full_unstemmed KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8(+) T-cell-dependent antitumor immunity
title_short KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8(+) T-cell-dependent antitumor immunity
title_sort klf5 inhibition potentiates anti-pd1 efficacy by enhancing cd8(+) t-cell-dependent antitumor immunity
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008740/
https://www.ncbi.nlm.nih.gov/pubmed/36923542
http://dx.doi.org/10.7150/thno.82182
work_keys_str_mv AT wuqi klf5inhibitionpotentiatesantipd1efficacybyenhancingcd8tcelldependentantitumorimmunity
AT liuzhou klf5inhibitionpotentiatesantipd1efficacybyenhancingcd8tcelldependentantitumorimmunity
AT gaozhijie klf5inhibitionpotentiatesantipd1efficacybyenhancingcd8tcelldependentantitumorimmunity
AT luoyao klf5inhibitionpotentiatesantipd1efficacybyenhancingcd8tcelldependentantitumorimmunity
AT lifubing klf5inhibitionpotentiatesantipd1efficacybyenhancingcd8tcelldependentantitumorimmunity
AT yangchuanyu klf5inhibitionpotentiatesantipd1efficacybyenhancingcd8tcelldependentantitumorimmunity
AT wangtiantian klf5inhibitionpotentiatesantipd1efficacybyenhancingcd8tcelldependentantitumorimmunity
AT mengxiangyu klf5inhibitionpotentiatesantipd1efficacybyenhancingcd8tcelldependentantitumorimmunity
AT chenhaijun klf5inhibitionpotentiatesantipd1efficacybyenhancingcd8tcelldependentantitumorimmunity
AT lijuanjuan klf5inhibitionpotentiatesantipd1efficacybyenhancingcd8tcelldependentantitumorimmunity
AT kongyanjie klf5inhibitionpotentiatesantipd1efficacybyenhancingcd8tcelldependentantitumorimmunity
AT dongchao klf5inhibitionpotentiatesantipd1efficacybyenhancingcd8tcelldependentantitumorimmunity
AT sunsi klf5inhibitionpotentiatesantipd1efficacybyenhancingcd8tcelldependentantitumorimmunity
AT chenceshi klf5inhibitionpotentiatesantipd1efficacybyenhancingcd8tcelldependentantitumorimmunity